Media & Press2019-09-17T16:08:49-05:00

    Bexion Pharmaceuticals, Inc. To Present Clinical Data at 2019 NORD Annual Meeting

    September 4, 2019|

    Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for ... Read More

      Bexion Pharmaceuticals Experiences Robust Enrollment of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

      March 5, 2019|

      FOR IMMEDIATE RELEASE Covington, KY ~ March 5, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites. In the first few weeks of opening Part 3, over 20 GI and ... Read More

        Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

        February 22, 2019|

        FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer. This trial was designed to determine the maximum tolerated dose of BXQ-350 and to characterize its safety and pharmacokinetics. The Phase I ... Read More

          Dr. Ray Takigiku Honored as Finalist at the 2019 Healthcare Hero Awards

          |

          FOR IMMEDIATE RELEASE Covington, KY – 22 February 2019 Dr. Ray Takigiku, Founder and CEO of Bexion Pharmaceuticals, Inc. was honored as a finalist in the category of “Entrepreneur” of the Year by the Cincinnati Business Courier at the 2019 Healthcare Hero Awards Celebration. These annual awards honor individuals and organizations that have improved the ... Read More

            Bexion Pharmaceuticals, Inc. Presents Clinical Data at 2018 SNO Annual Meeting

            November 19, 2018|

            FOR IMMEDIATE RELEASE Covington, KY ~ 19 November 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster review and a second case study poster were presented at the Society of Neuro-Oncology (SNO) Annual Meeting held November 16-18 in New ... Read More

              Bexion Pharmaceuticals, Inc. Represented at 15th Annual BioNetwork Partnering Summit

              October 18, 2018|

              National Cancer Institute (NCI) Selects Bexion as a Presenting Company FOR IMMEDIATE RELEASE [Covington, KY ~ October 18, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announces that Dr. Ray Takigiku, Founder and CEO of the Company presented recently at the 15th Annual BioNetwork Partnering Summit, held ... Read More

                Bexion Pharmaceuticals, Inc. Announces Grant from CancerFree KIDS

                June 19, 2018|

                CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 Sometimes things come full circle. Fourteen years ago, CancerFree KIDS awarded its very first research grant to a young investigator at Cincinnati Children’s Hospital Medical Center (CCHMC) to study a long shot idea that no one ... Read More

                  Bexion Pharmaceuticals, Inc. Announces Data at 2018 ASCO Annual Meeting from Ongoing Phase I BXQ-350 Clinical Trial

                  June 12, 2018|

                  FOR IMMEDIATE RELEASE Covington, KY ~ June 12, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of its ongoing Phase I Safety Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting Poster Session, held in ... Read More

                    Bexion Pharmaceuticals, Inc. To Present Clinical Data at 2018 ASCO Annual Meeting

                    May 22, 2018|

                    FOR IMMEDIATE RELEASE Covington, KY ~ May 22,2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature one clinical poster presentation and three online publications at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 1-5 in Chicago, IL. The ... Read More

                      Bexion Pharmaceuticals, Inc. Presentations Accepted at 2018 ASCO Annual Meeting

                      April 16, 2018|

                      FOR IMMEDIATE RELEASE Covington, KY April 16, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain tumors, announced today that the four abstracts submitted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago, Illinois have all been accepted. One of the accepted presentations ... Read More

                        Bexion Pharmaceuticals, Inc. to Present at the 25th Annual Meeting of Future Leaders in the BioTech Industry

                        February 14, 2018|

                        FOR IMMEDIATE RELEASE [Covington, KY ~ February 14, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 at the Future Leaders in the BioTech Industry ... Read More

                          Bexion Pharmaceuticals Honoree at American Cancer Society Annual Ball

                          November 16, 2016|

                          COVINGTON, KY. November 16, 2016 – Bexion Pharmaceuticals was awarded the “Medical Professional Award” at the American Cancer Society’s Annual Striders’ Ball held on November 5, 2016. This is the first time the honor has been bestowed on a company versus an individual medical professional. “We are greatly honored to have been nominated, and to ... Read More

                            Bexion Pharmaceuticals Finalist for Cancer Support Community’s Inspiration in Cancer Research Award

                            November 8, 2016|

                            COVINGTON, KY. November 8, 2016 – Bexion Pharmaceuticals was honored as a finalists for the “2016 Inspiration in Cancer Research Award” at the Cancer Support Community’s (CSC) annual Evening of Hope Gala, held on October 29, 2016. “The Bexion team is honored to be a finalist for the CSC annual Inspiration Award,” stated Dr. Ray ... Read More

                              Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute

                              September 20, 2016|

                              FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY. September 20, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) and the University of Cincinnati Cancer Institute (UCCI) announced today the dosing of the first patient in the Phase I trial of BXQ-350, a novel anti-cancer therapeutic agent. This open-label trial will include adult patients with advanced solid ... Read More

                                Bexion Pharmaceuticals and CTI Clinical Trial and Consulting Services Announce Collaboration on First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

                                September 9, 2016|

                                FOR IMMEDIATE RELEASE [Cincinnati, OH ~ September 8, 2016] Bexion Pharmaceuticals (Bexion) and CTI Clinical Trial and Consulting Services (CTI) announce their collaboration on the First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. The FDA recently cleared Bexion’s application to initiate the open-label trial that will include adult patients with advanced ... Read More

                                  Bexion Pharmaceuticals Receives FDA Clearance For the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer

                                  July 18, 2016|

                                  FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, July 18, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) announced today that the U.S. Food and Drug Administration (FDA) cleared Bexion’s application to initiate a First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. This open-label trial will include adult patients with advanced solid ... Read More

                                    Bexion Pharmaceuticals Wins 2015 Tibbetts Award From the Small Business Administration

                                    June 1, 2015|

                                    FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, June 1, 2015 -- Bexion Pharmaceuticals LLC announced that the Small Business Administration (SBA) has awarded the Company the prestigious Tibbetts Award, recognizing Bexion as a “Model of Excellence” for the Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Awarded ... Read More

                                      Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme from FDA

                                      February 16, 2015|

                                      FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, Feb. 16, 2015 -- Bexion Pharmaceuticals LLC announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for Saposin C, active  ingredient in its proprietary drug BXQ-350 for the potential treatment of glioblastoma multiforme. The FDA’s Office of ... Read More